Featured Research

from universities, journals, and other organizations

Diabetes' Link To Obesity Broken In Mice

Date:
March 2, 2005
Source:
Washington University School Of Medicine
Summary:
Scientists at Washington University School of Medicine in St. Louis used genetically modified mice to uncover a potentially important link between diabetes and obesity.

St. Louis, Feb. 15, 2005 -- Scientists at Washington University School of Medicine in St. Louis used genetically modified mice to uncover a potentially important link between diabetes and obesity.

By genetically altering production of a factor found in skeletal muscle, scientists produced mice that can't get fat but do develop early signs of diabetes. Reversing the alteration produced mice that can become obese but do not develop diabetes.

The findings provide important insights for scientists struggling to find new ways to cope with the unprecedented epidemic of obesity now spreading through the United States and other nations. Obesity brings with it a range of health consequences including sharply increased risk of type 2 diabetes, the most common form of diabetes.

Scientists broke the link to improve their understanding of the network of factors that lead from obesity to the onset of diabetes. Based on what they learned, they applied a drug treatment in their new transgenic mice and in a different, previously established mouse line that suffers from obesity and a diabetes-like condition. In both groups, the drug increased insulin sensitivity, which is a primary goal of diabetes treatment.

"These results confirm that the links between obesity and diabetes show great promise as targets for new therapies that act as 'metabolic modulators' in muscle," says senior author Daniel P. Kelly, M.D., professor of medicine, of pediatrics and of molecular biology and pharmacology.

The study appears in the February 2005 issue of Cell Metabolism. It reveals new details of the activities of the peroxisome proliferator-activated receptors (PPARs), a family of receptors that affects the way cells respond to energy resources.

Diabetes disrupts the body's ability to manage energy resources including both fat and sugar. Insulin is a primary regulator of these resources. When the intake of calories exceeds the ability of the body to store them, insulin does not work as well, leading to an increase in blood sugar levels. The work by Kelly's group shows that this problem starts by diversion of fats to muscle, triggering an abnormal activation of PPAR. PPAR in turn sends signals to the cells to stop responding to insulin, resulting in hazardously high blood sugar levels.

Kelly's research group had previously shown that a member of the PPAR family, PPAR-alpha, was unusually active in heart and skeletal muscle of diabetic mice. PPAR-alpha normally becomes active in response to fats. It "revs up" the machinery cells use to make energy from fat, according to Kelly.

"It's an adaptive response that helps the cell deal with all the fat that's coming in, but our notion was that it might also play a role in the development of diabetes," he explains. "We thought PPAR-alpha might also be telling cells, look, we have all this fat coming in, so we're not going to need glucose to make energy, so let's shut down glucose burning. And that's exactly what happens in diabetes."

To test their ideas, Kelly and lead author Brian N. Finck, Ph.D., research instructor in medicine, engineered a line of mice with extra PPAR-alpha in their skeletal muscle. They found the mice's skeletal muscle cells could "chew up" fat at remarkable speeds, preventing obesity even when the mice were fed a high-fat diet.

Although they were lean, the mice were also "on their way to becoming diabetic," according to Kelly. Insulin resistance and glucose intolerance -- two key harbingers of diabetes -- increased in the mice. Kelly's group traced the glucose intolerance to PPAR-alpha's ability to shut down genes involved in glucose uptake and use.

When Kelly's lab tested a line of mice where PPAR-alpha had been genetically knocked out, they found the reverse was true. The mice could get just as obese as normal mice on a high-fat diet, but they did not develop early signs of diabetes.

Based on what they learned about PPAR-alpha's effects, scientists gave a drug that inhibited an important enzyme in the processes that let muscle cells make energy from fat. PPAR-alpha normally activates this enzyme as part of its efforts to accelerate fat metabolism, and blocking it essentially tricked the cell into thinking that PPAR-alpha was no longer activated. Insulin sensitivity increased as a result.

To follow up, Kelly's lab is attempting to rescue the new mouse line from glucose intolerance and insulin resistance. PPAR-alpha seems to convince cells that they don't need glucose because they have plenty of energy available from fat, so Kelly will try to increase energy demand or trick cells into thinking they have less energy available.

"One obvious experiment is to exercise the animals, increasing their muscle energy requirements to see if we can make them more insulin sensitive," Kelly says. "Another option is to develop ways to decrease the cellular accumulation of a compound known as ATP, which is the key product of cellular energy-making processes."

###

Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP. "A potential link between muscle peroxisome proliferator-activated receptor alpha signaling and obesity-related diabetes." Cell Metabolism, February 2005.

Funding from the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases supported this research.

Washington University School of Medicine's full-time and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked second in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.


Story Source:

The above story is based on materials provided by Washington University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Washington University School Of Medicine. "Diabetes' Link To Obesity Broken In Mice." ScienceDaily. ScienceDaily, 2 March 2005. <www.sciencedaily.com/releases/2005/02/050222194340.htm>.
Washington University School Of Medicine. (2005, March 2). Diabetes' Link To Obesity Broken In Mice. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/02/050222194340.htm
Washington University School Of Medicine. "Diabetes' Link To Obesity Broken In Mice." ScienceDaily. www.sciencedaily.com/releases/2005/02/050222194340.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins